Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27209211 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Wei-Chung Shia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular and Surgical Research, Department of Research, Changhua Christian Hospital, Changhua 50050, Taiwan. Hauptthemen laut MEDLINE: Reactive Oxygen Species, Quantum Dots, Breast Neoplasms, Graphite. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Changhua Christian Hospital.
Abstract (Originalsprache)
Oxidized graphene quantum dots (o-GQDs) alter viability and cell-cycle progression in breast cancer cells, yet the cellular programs underlying these effects remain incompletely defined. We exposed MCF-7 cells to 10 mg/L o-GQD for 72 h and integrated RNA sequencing with quantitative protein-marker, ROS, antioxidant-intervention, proteasome-inhibition, and puromycin-labeling analyses from independent experiments. Transcriptomic analyses showed significant negative enrichment of proliferative and cell-cycle programs (E2F Targets, G2M Checkpoint, MYC Targets V1), with complementary KEGG/Reactome evidence of attenuated estrogen-associated programs. Quantitative Western blotting showed dose-dependent reductions in ERα (to 41.36 ± 13.73% at 10 mg/L), p-RB (to 8.31 ± 10.39%), and Survivin (to 23.97 ± 19.01%), with p-ERK/ERK attenuation and marked γ-H2AX accumulation (345.21 ± 161.39%). The ROS-positive fraction rose from 6.86% to 30.46%; antioxidant co-treatment failed to rescue the phenotype and MG132 did not consistently restore protein markers, arguing against oxidative stress or proteasomal degradation as standalone drivers. Reduced puromycin labeling added a protein-homeostasis readout consistent with reduced nascent protein synthesis. BT-474 and MDA-MB-231 cells showed weaker or different marker responses. Together, these findings define a coordinated MCF-7 response spanning estrogen-associated and cell-cycle programs, survival markers, protein homeostasis, and cell fate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular and Surgical Research, Department of Research, Changhua Christian Hospital, Changhua 50050, Taiwan.
- Department of Chemical Engineering and Materials Science, Yuan Ze University, Taoyuan 32003, Taiwan.
ORCID-Profile: Wei-Chung Shia, Chien-Te Hsieh, Wan-Ling Chuang
Förderung
- Changhua Christian Hospital
Zitieren
APA
Shia, W. C., Hsieh, C. T., Yang, P. C., Chuang, W. L., & Shen, W. T. (2026). Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27209211
Vancouver
Shia WC, Hsieh CT, Yang PC, Chuang WL, Shen WT. Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27209211
BibTeX
@article{Shia2026,
author = {Shia, Wei-Chung and Hsieh, Chien-Te and Yang, Po-Chih and Chuang, Wan-Ling and Shen, Wan-Ting},
title = {Integrated Transcriptomic and Biochemical Analyses Reveal Coordinated Suppression of ER-Associated Survival Signaling and Activation of ROS-Mediated Stress Responses by Oxidized Graphene Quantum Dots in Estrogen Receptor-Positive Breast Cancer},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27209211}
}
EUVIMED